Michel Delforge is professor of Medicine in the Department of Hematology at the University of Leuven in Belgium. He trained in Leuven and at the University of Minnesota, USA, and obtained a doctoral degree in biomedical sciences. Dr Delforge is currently chairman of the Cancer Institute Leuven and clinical head of the Department of Hematology where he directs the plasma cell dyscrasia unit. He is also a senior clinical investigator, chairman of the Belgian Myeloma Working Party, and active member of the Intergroupe Francophone du Myélome, HOVON (Hemato-Oncology Foundation for Adults in the Netherlands), and the International Myeloma Working Group. He holds the Luc Fraiture Chair in Hematology at the University of Leuven, and has authored or coauthored more than 100 manuscripts and several book chapters in the field of hematology. He is reviewer for several international journals in the field of hematology.